SCHEMBL4718950

SCHEMBL4718950

Clc1cc(-c2ccncc2)cc(Nc2cccc3cnccc23)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
ALDH1A1 P00352 4/20 0.44
LMNA P02545 4/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 2/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44
BLM P54132 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TRPV1 Q8NER1 6/20 0.43
MAPT P10636 4/20 0.43
KDM4E B2RXH2 3/20 0.43
CASP3 P42574 2/20 0.43
SENP7 Q9BQF6 2/20 0.43
SENP6 Q9GZR1 2/20 0.43
SENP8 Q96LD8 1/20 0.43
PRKCH P24723 1/20 0.42
PRKCE Q02156 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15452589 0.80 CDK2 (0.50) CCR4SMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL4717939 0.78 MAPK10 (0.50) CCR4SMN1; SMN2ALDH1A1HTTBLM
SCHEMBL4717951 0.76 ALDH1A1 (0.45) CCR4SMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL4717857 0.76 TRPV1 (0.57) CCR4SMN1; SMN2ALDH1A1TRPV1MAPT
SCHEMBL4719798 0.76 TRPV1 (0.54) TRPV1ROCK2
SCHEMBL4716131 0.75 TRPV1 (0.62) CCR4TRPV1LATS1LATS2
SCHEMBL25175478 0.73 ADRA2A (0.70) CCR4SMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL4715596 0.72 TRPV1 (0.58) SMN1; SMN2ALDH1A1TRPV1MAPTKDM4E
SCHEMBL4716256 0.72 ALDH1A1 (0.51) CCR4SMN1; SMN2ALDH1A1LMNATRPV1
SCHEMBL4717106 0.71 TRPV1 (0.43) CCR4SMN1; SMN2ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 CCR4 366/4885SMN1; SMN2 2309/4885ALDH1A1 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.